NSW funds gene therapy startup’s ALS research push

A $2 million grant from the NSW Emerging Technology Commercialisation Fund will help Celosia Therapeutics advance its second gene therapy for motor neurone disease, the largest single award in the first round of the program. The startup, a Macquarie University spinout, was the only recipient to secure the maximum funding from the $7 million pool shared among six companies. More than 250 businesses applied to the state government program, highlighting the competitive nature of the initiative.
The grant will support preclinical studies, manufacturing development, and expansion of Celosia’s pipeline alongside its lead therapy, CTx1000, currently in a phase 1b trial for sporadic amyotrophic lateral sclerosis (ALS). Celosia CEO Dr Kathryn Sunn stated the funding would help expand its MND pipeline, supporting candidate development and manufacturing work. The company will collaborate with the NSW Viral Vector Manufacturing Facility over two years to scale production and test quality before future clinical testing, ensuring reliable large-scale manufacturing processes.
Celosia’s research focuses on TDP-43, a protein that forms toxic clumps in 97% of ALS cases. The therapy aims to clear these clumps while preserving functional protein levels in nerve cells. The biotech grew out of research by Macquarie University professors Lars Ittner and Yazi Ke, whose work identified TDP-43 as a key target. The startup previously raised $16.75 million in a 2024 Series A round, led by Uniseed and backed by hedge fund manager Iomar Barrett, who was living with ALS.
The $20 million fund, part of NSW’s Innovation Blueprint 2035, runs for three years, with the next funding round opening in 2027. Other recipients include Agscent ($1.25 million), which will commercialize its one-minute cattle breath test for bovine respiratory disease in feedlots, having previously raised $5 million at a $26.9 million valuation. Hullbot ($750,000) is building a ship-mounted docking system for hull-cleaning robots, having secured a $6 million Series A last year to reduce fuel costs by preventing marine growth buildup. Syenta, an ANU spinout, received funding for finer chip connections to improve performance and energy efficiency, following a $36 million Series A earlier this year.
